Literature DB >> 9556621

Activation of ErbB4 by the bifunctional epidermal growth factor family hormone epiregulin is regulated by ErbB2.

D J Riese1, T Komurasaki, G D Plowman, D F Stern.   

Abstract

Epiregulin (EPR) is a recently described member of the epidermal growth factor (EGF) family of peptide growth factors. The ever expanding size of the EGF family has made distinguishing the activities of these hormones paramount. We show here that EPR activates two members of the ErbB family of receptor tyrosine kinases, epidermal growth factor receptor (EGFR) and ErbB4. Therefore by these criteria, EPR is qualitatively similar to another EGF family hormone, betacellulin (BTC). Yet, here we also demonstrate quantitative differences between EPR and BTC. EPR stimulates higher levels of EGFR phosphorylation than does BTC, whereas BTC stimulates higher levels of ErbB4 phosphorylation than does EPR. Moreover, the EPR and BTC dose response curves show that although EGFR is more sensitive to EPR than is ErbB4, ErbB4 is more sensitive to BTC than is EGFR. Finally, ErbB2, which is not activated by EPR when expressed on its own, increases the sensitivity of ErbB4 for activation by EPR. Therefore, these results establish that EPR exhibits novel activities and modes of regulation, which may have significant implications for EPR function in vivo.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9556621     DOI: 10.1074/jbc.273.18.11288

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

Review 1.  ErbB-4: a receptor tyrosine kinase.

Authors:  W Zhou; G Carpenter
Journal:  Inflamm Res       Date:  2002-02       Impact factor: 4.575

2.  The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors.

Authors:  L N Klapper; S Glathe; N Vaisman; N E Hynes; G C Andrews; M Sela; Y Yarden
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

Review 3.  Form and function of developing heart valves: coordination by extracellular matrix and growth factor signaling.

Authors:  Joyce A Schroeder; Leslie F Jackson; David C Lee; Todd D Camenisch
Journal:  J Mol Med (Berl)       Date:  2003-06-25       Impact factor: 4.599

4.  Phenotypic variation resulting from a deficiency of epidermal growth factor receptor in mice is caused by extensive genetic heterogeneity that can be genetically and molecularly partitioned.

Authors:  Karen E Strunk; Vicky Amann; David W Threadgill
Journal:  Genetics       Date:  2004-08       Impact factor: 4.562

5.  Activated human hydroxy-carboxylic acid receptor-3 signals to MAP kinase cascades via the PLC-dependent PKC and MMP-mediated EGFR pathways.

Authors:  Q Zhou; G Li; X Y Deng; X B He; L J Chen; C Wu; Y Shi; K P Wu; L J Mei; J X Lu; N M Zhou
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

6.  SRC-family tyrosine kinases in wound- and ligand-induced epidermal growth factor receptor activation in human corneal epithelial cells.

Authors:  Ke-Ping Xu; Jia Yin; Fu-Shin X Yu
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-07       Impact factor: 4.799

7.  Lysophosphatidic acid promoting corneal epithelial wound healing by transactivation of epidermal growth factor receptor.

Authors:  Ke-Ping Xu; Jia Yin; Fu-Shin X Yu
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-02       Impact factor: 4.799

8.  Amphiregulin-deficient mice develop spasmolytic polypeptide expressing metaplasia and intestinal metaplasia.

Authors:  Ki Taek Nam; Hyuk-Joon Lee; Hoyin Mok; Judith Romero-Gallo; James E Crowe; Richard M Peek; James R Goldenring
Journal:  Gastroenterology       Date:  2008-12-13       Impact factor: 22.682

9.  Epiregulin is a potent vascular smooth muscle cell-derived mitogen induced by angiotensin II, endothelin-1, and thrombin.

Authors:  D S Taylor; X Cheng; J E Pawlowski; A R Wallace; P Ferrer; C J Molloy
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

Review 10.  ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer.

Authors:  David F Stern
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-05-03       Impact factor: 2.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.